Stroke prevention in patients with atrial fibrillation (AF) is one pillar of the management of
this common arrhythmia. Substantial advances in the epidemiology and associated …

The consensus of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in
atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for …

Rheumatic heart disease (RHD) is the underlying cause of a significant proportion of atrial
fibrillation (AF) in the low-and middle-income countries, while nonvalvular AF is the most …

The non-vitamin K antagonist oral anticoagulants (NOACs) dabigatran, rivaroxaban,
apixaban, and edoxaban have transformed the management of atrial fibrillation (AF), but are …

Background: Direct oral anticoagulants (DOACS) are approved for use in non-valvular atrial
fibrillation (AF). This systematic review and meta-analysis aimed to evaluate the efficacy and …

Background/Objectives: Non-vitamin K antagonist oral anticoagulants (NOACs) have
demonstrated similar effectiveness and safety profiles to vitamin K antagonists (VKAs) in …

Atrial fibrillation (AF) is a common arrhythmia in clinical practice, and oral anticoagulation is
the cornerstone of stroke prevention in AF. Direct oral anticoagulants (DOAC) significantly …

VKA remains the standard of care for patients with moderate to severe rheumatic MS who
have concomitant AF. Rates of stroke in anticoagulated patients with rheumatic MS and AF …

Background Several studies have summarized the clinical performance of direct oral
anticoagulants (DOACs) in atrial fibrillation (AF) patients with mitral stenosis or aortic …

Anticoagulation is essential for patients with mechanical prosthetic heart valves. However,
controversy exists in clinical practice regarding the use of anticoagulant and/or antiplatelet …